EIA: Oil Price to Average Nominal $200 by 2035

Source: Automated Trader, Brai Odion-Esene (12/16/10)

"Oil prices to rise slowly as global economy recovers and demand grows."

After a sharp fall in 2008, oil prices will rise gradually as the global economy recovers and global demand grows "more rapidly" that liquids supplies from non-OPEC producers, the EIA predicted Thursday.

In its Annual Energy Outlook Reference case, the EIA presented updated projections for U.S. energy markets through 2035. It estimates the average real price of crude oil will be $125/barrel "in 2009 dollars," or about $200/barrel in nominal dollars.

In the report, real prices (in 2009 dollars) for gasoline and diesel increase from $2.35 and $2.44 per gallon in 2009 to $3.69 and $3.89/gallon, respectively, in 2035.

"The AEO2011 Reference case assumes that limitations on access to energy resources restrain the growth of non-OPEC conventional liquids production between 2009 and 2035, and that OPEC targets a relatively constant market share of total world liquids production," the EIA said. It added that the degree to which non-OPEC countries and countries outside the OECD restrict access to potentially productive resources contributes to world oil-price uncertainty. Other factors causing uncertainty include OPEC investment decisions, which will affect future prices and the economic viability of unconventional liquids.

The EIA projects world liquids consumption to grow from 83.7 million barrels per day (Mbbls./d) in 2009 to 110.8 Mbbls./d in 2035, with most of the growth expected from non-OECD countries/regions led by China, India and the Middle East.

On the supply side, the EIA noted that in several resource-rich regions—Brazil, Russia and Kazakhstan—high oil prices, expanded infrastructure and further exploration and drilling investment should contribute to additional non-OPEC oil production.

Within the U.S., crude oil production is projected to rise from 5.4 Mbbls./d in 2009 to 6.1 Mbbls./d in 2019, before declining slightly through 2035. The EIA sees increases in production coming from onshore enhanced-oil recovery projects and shale oil plays.

Novavax Shares Shoot 65% Higher on Phase 3 COVID-19 Vaccine Trial's 89.3% Effectiveness
Source: Streetwise Reports (01/29/2021)

Novavax Inc. shares established a new 52-week high after the firm's COVID-19 vaccine demonstrated an 89.3% efficacy rate in a Phase 3 trial in the U.K. and also showed efficacy against the South African variant in a Phase 2b trial.

Abiomed Shares Gain 8% After Firm Announces Record Q3 Revenue of $232 Million
Source: Streetwise Reports (01/28/2021)

Shares of cardiac medical device maker Abiomed Inc. traded higher after the company reported record revenue for Q3/21 despite the impact from COVID-19.

Sorrento Shares Rise 35% After Firm Posts Positive Data from Phase 1b ICU COVID-19 Trial
Source: Streetwise Reports (01/27/2021)

Shares of Sorrento Therapeutics traded higher after the company released positive preliminary results from it of Phase 1b COVI-MSC™ Study for treatment of hospitalized ICU COVID-19 patients.

Junior Mining Sector 'the Best Value in the Space'
Source: Streetwise Reports (01/27/2021)

The StreetSmart Live! Broadcast on Jan. 26, 2021, focused on metals and why now is a good time for investors to be looking at them and the mining space. John Newell, independent analyst and portfolio manager, and John Feneck, mining sector expert and president of Feneck Consulting, addressed the status of the current metals market. CEOs of the three metals-focused companies comprising the Metallic Group of Companies—Group Ten Metals, Metallic Minerals and Granite Creek Copper—discussed their projects.

Vir Shares Climb 48% on Initial Phase 1 Chronic Hepatitis B Trial Data
Source: Streetwise Reports (01/26/2021)

Vir Biotechnology shares traded higher after the company reported data from its Phase 1 Chronic Hepatitis B Study that showed VIR-3434 significantly and rapidly reduced hepatitis B surface antigen.

Aurinia Pharma Shares Open at 52-Week High as FDA Approves Adult Lupus Nephritis Drug
Source: Streetwise Reports (01/25/2021)

Shares of Aurinia Pharmaceuticals traded 30% higher after the company reported that the U.S. Food and Drug Administration approved its LUPKYNIS™ (voclosporin) for use in treating adults with active lupus nephritis.

AzurRx Doses First Two People in Expanded Phase 2b Trial of Cystic Fibrosis Patients
Source: Streetwise Reports (01/22/2021)

AzurRx BioPharma shares traded 45% higher after the firm advised it had dosed the first two patients in its Phase 2b OPTION 2 Extension Study of MS1819 for treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis.

NGL Energy Shares Rise 21% as It Seeks to Raise $2.05 Billion from Senior Secured Note Offering
Source: Streetwise Reports (01/21/2021)

Shares of NGL Energy Partners LP traded higher after the firm made a series of announcements over the past three days regarding an update on financial operations, a settlement with a customer in bankruptcy, a quarterly Class D unit distribution and a $2.05 billion senior secured debt offering.

Explorer Discovers New Gold Mineralization at Abitibi Gold Belt Property
Source: Streetwise Reports (01/21/2021)

iMetal Resources is setting out to see if the multi-million ounce gold resource next door continues onto its Gowganda West property in Ontario.

Gritstone Oncology Licenses LNP Platform from Genevant Sciences to Develop COVID-19 Vaccine
Source: Streetwise Reports (01/20/2021)

Shares of Gritstone Oncology reached a new 52-week high price after the company advised it entered into a non-exclusive licensing agreement with Genevant Sciences to develop and commercialize self-amplifying RNA vaccines for use against SARS-CoV-2.